One month of cytisinicline-induced smoking cessation significantly improved arterial stiffness, endothelial function, and cardiac performance in smokers (p<0.05).
Does cytisinicline improve arterial stiffness, endothelial function, and cardiac performance in healthy smokers?
Cytisinicline-induced smoking cessation over one month significantly improves surrogate markers of arterial stiffness, endothelial function, and cardiac performance in healthy smokers.
Absolute Event Rate: 0% vs 0%
Abstract Background Cytisinicline is a partial agonist of nicotinic acetylcholine receptors (nAChRs), used for smoking cessation. Purpose We investigated the effects of cytisinicline on arterial stiffness, endothelial function and cardiac performance. Methods Sixty healthy smokers attending our smoking cessation unit were recruited, of which n=30 smokers initiated cytisinicline and n=30 unwilling to quit served as controls. Both groups were matched for age, sex, and pack-years. We measured at baseline and at 1-month follow-up: a) Smoking status: self-reported smoking burden and exhaled carbon monoxide (eCO), b) Arterial stiffness: carotid-femoral pulse wave velocity (PWV), central aortic and pulse pressure, c) Endothelial function: perfused boundary region (PBR) of the sublingual microvessels with diameter range 20-25 μm (Increased PBR indicates shedding of glycocalyx layer) and brachial artery flow-mediated dilation (FMD), d) Cardiac Performance: By Doppler Echocardiography the E-wave, early diastolic velocity (E'), E/E' ratio, global longitudinal strain (GLS), and e) the PWV/GLS ratio, to assess Ventriculoarterial Interaction. Results We enrolled participants aged 49± 8 years old, 34/60 (57%) males, had28±8 pack-years. The baseline measurements of arterial stiffness, endothelial function, cardiac performance did not differ between the groups (p0.05). At 1-month follow-up, 29/30 cytisinicline users ceased smoking. Their eCO levels decreased significantly (p0.001) post-treatment whilst remained unchanged in controls (p0.05). Compared to baseline, cytisinicline resulted in improvement of PWV, PP, cSBP, FMD, GLS, PWV/GLS, E/E’ and PBR20-25 (p0.05 for all comparisons, Table). No difference of the above markers was observed in controls (p0.05), apart from increase PBR20-25 (p=0.045). Conclusion The use of Cytisinicline for one month in smokers resulted in amelioration of arterial stiffness, endothelial function, cardiac performance in conjunction with safe and effective smoking cessation.
Ikonomidis et al. (Sat,) reported a other. One month of cytisinicline-induced smoking cessation significantly improved arterial stiffness, endothelial function, and cardiac performance in smokers (p<0.05).